All Antiparkinsonian Drugs: Compilation

Explore our entire animation video library at: https://www.nonstopneuron.com/
All videos from central nervous system pharmacology: https://www.nonstopneuron.com/post/ph...

Video Summary:
In Parkinsonism is disease neurons from substantia nigra to corpus striatum of basal ganglia are lost. This results in reduced dopamine activity in basal ganglia causing movement problems like hypokinesia, rigidity and tremors. Comint to pharmacology. There is no permanent cure to this drug. However it can be symptomatically treated with levodopa, peripheral dopa decarboxylase inhibitors like carbidopa and benserazide, COMT inhibitors like tolcapone and entacapone, amantadine, dopamine receptor agonists like bromocriptine, pergolide, ropinirole and pramipexole, MAO-B inhibitors like selegiline and rasagiline and centrally acting antimuscarinic agents.
Video Summary:
Pathophysiology of Parkinson’s disease was covered in first video. Antiparkinsonian drugs are levodopa, peripheral dopa decarboxylase inhibitors like carbidopa and benserazide, COMT inhibitors like tolcapone and entacapone, amantadine, dopamine receptor agonists like bromocriptine, pergolide, ropinirole and pramipexole, MAO-B inhibitors like selegiline and rasagiline and centrally acting antimuscarinic agents.
Levodopa is precursor of dopamine. So, when given to patients of Parkinson’s disease, remaining healthy neurons synthesize more dopamine from levodopa. This increases dopamine activity in brain and thus relieves symptoms. However, most of the levodopa is lost due to its peripheral conversion into dopamine by peripheral dopa decarboxylase and degradation by catechol o methyl transferase. To limit this loss DDC inhibitors like carbidopa and benserazide, and COMT inhibitors like tolcapone and entacapone can be used.
Video Summary:
This 3rd video on antiparkinsonian drugs describes amantadine, dopamine agonists, MAO-B inhibitors and centrally acting antimuscarinic agents.
Amantadine is primarily an antiviral agent. However it works in parkinsonism also. It increased dopamine release and decreases uptake. Has antimuscarinic activity and also block NMDA receptors. Dopamine agonists like bromocriptine, ropinirole and pramipexole stimulate the dopamine receptors directly. MAO-B inhibitors like selegiline and rasagiline inhibit degradation of dopamine by MAO-B enzyme. Centrally acting anticholinergic agents bring cholinergic activity in brain, in balance with dopamine activity.

● Antiparkinsonian Drugs:
• AntiParkinsonian Drugs 2: Levodopa, Carbidopa, Tolcapone & Entacapone:    • Your ONE-STOP Solution to Learn AntiP...  
• AntiParkinsonian Drugs 3: Amantadine, Dopamine Agonists, MAO-B Inhibitors, Antimuscarinic Agents:    • AntiParkinsonian drugs 3: Amantadine,...  
• Compilation of all videos on Antiparkinsonian Drugs:    • All Antiparkinsonian Drugs: Compilation  

● Random videos related to Antiparkinsonian drugs
• Journey of Levodopa:    • Journey of Levodopa  
• Dilemma of Dopamine:    • Dilemma of Dopamine  

● Follow me at:
• Facebook:   / nonstopneuron  
• Instagram:   / nonstopneuron  

DISCLAIMER: This video is for education purpose only. Although every effort is made to ensure accuracy of material, viewer should refer to the appropriate regulatory body/authorised websites, guidelines and other suitable sources of information as deemed relevant and applicable. In view of possibility of human error or changes in medical science, any person or organization involved in preparation of this work accepts no responsibility for any errors or omissions or results obtained from use of information in this video.